Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
11
×
clinical trials
11
×
life sciences
national blog main
raleigh-durham blog main
11
×
raleigh-durham top stories
boston blog main
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
eli lilly
novartis
bristol-myers squibb
glaxosmithkline
cancer
gene therapy
pfizer
roche
startups
abeona therapeutics
What
roundup
bio
drug
fda
new
won
approval
decades
drugs
migraine
biotech
cancer
class
days
eli
giant
lung
medical
news
pharmaceutical
pricing
according
acute
addresses
advanced
advantages
akcea
alliance
alzheimer’s
american
amgen
annual
appetite
arguments
arrival
ash
august
award
bar
big
Language
unset
Current search:
amgen
×
" clinical trials "
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines